Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 7/20 | 0.70 |
| ▸ | CA1 | P00915 | 7/20 | 0.70 |
| ▸ | CA2 | P00918 | 7/20 | 0.70 |
| ▸ | CA9 | Q16790 | 7/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | SUCNR1 | Q9BXA5 | 7/20 | 0.51 |
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10568289 | 0.91 | CA12 (0.69) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL24920675 | 0.89 | CA12 (0.62) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL24921300 | 0.89 | CA12 (0.60) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL14313674 | 0.89 | CA12 (0.70) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL2147505 | 0.87 | CA12 (0.69) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL16245772 | 0.87 | CA12 (0.73) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL30212242 | 0.87 | CA12 (0.57) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL25028474 | 0.86 | CA12 (0.70) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL12461819 | 0.86 | CA12 (0.67) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL15856108 | 0.86 | CA12 (0.67) | CA12CA1CA2CA9SUCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667621-B2 | Antiestrogen compounds | STEVENS INSTITUTE OF TECHNOLOGY (US) | 2023-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667621-B2 | Antiestrogen compounds | ESR1, ESR2, ESRRG | CA12 3387/4885CA1 2479/4885CA2 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.